- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech The Future Is Online
U.S. Pharmaceuticals & Biotech The Future Is Online
UPDATED Dec 15, 2023
A list of some of the world's largest online retailers.
323 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| IMGNImmunoGen | US$29.45 | 0.8% | 489.0% | US$7.9b | US$29.48 | PS27.4x | E59.4% | n/a | ||
| JAZZJazz Pharmaceuticals | US$121.50 | 0.9% | -23.0% | US$7.6b | US$193.00 | PE95.7x | E25.5% | n/a | ||
| STVNStevanato Group | US$28.31 | 1.8% | 61.8% | US$7.5b | US$33.93 | PE46.5x | E14.6% | 0.2% | ||
| CTLTCatalent | US$41.48 | 11.6% | -6.3% | US$7.5b | US$49.29 | PS1.8x | E83.8% | n/a | ||
| CERECerevel Therapeutics Holdings | US$41.30 | 0.2% | 62.9% | US$7.5b | US$36.60 | PB27.3x | E-6.1% | n/a | ||
| EXELExelixis | US$23.41 | 6.4% | 46.9% | US$7.3b | US$25.75 | PE79.1x | E33.9% | n/a | ||
| IONSIonis Pharmaceuticals | US$49.70 | 2.1% | 28.6% | US$7.1b | US$54.38 | PS11.6x | E25.3% | n/a | ||
| NTRANatera | US$59.01 | 1.5% | 36.2% | US$7.1b | US$71.94 | PS7.2x | E46.5% | n/a | ||
| BBIOBridgeBio Pharma | US$39.37 | 21.1% | 325.2% | US$6.8b | US$48.00 | PS726.5x | E32.1% | n/a | ||
| ASNDAscendis Pharma | US$120.97 | 12.3% | 2.0% | US$6.8b | US$141.56 | PS41.3x | E61.7% | n/a | ||
| ELANElanco Animal Health | US$13.76 | 7.5% | 14.5% | US$6.8b | US$13.44 | PS1.6x | E96.5% | n/a | ||
| TXG10x Genomics | US$53.47 | 9.5% | 50.2% | US$6.3b | US$56.50 | PS10.7x | E58.2% | n/a | ||
| ITCIIntra-Cellular Therapies | US$65.44 | 8.5% | 28.2% | US$6.3b | US$77.36 | PS15x | E72.5% | n/a | ||
| APLSApellis Pharmaceuticals | US$52.68 | -16.0% | -0.6% | US$6.2b | US$66.69 | PS22.9x | E72.5% | n/a | ||
| IMVTImmunovant | US$42.74 | 9.1% | 168.6% | US$6.2b | US$49.38 | PB24.6x | E34.7% | n/a | ||
| PCVXVaxcyte | US$60.56 | 6.9% | 32.2% | US$5.8b | US$66.00 | PB4.1x | E-9.6% | n/a | ||
| ABCMAbcam | US$23.99 | 0.08% | 54.7% | US$5.5b | US$23.66 | PE1758.5x | E39.3% | 0% | ||
| ISEEIVERIC bio | US$39.95 | 0.9% | 236.3% | US$5.5b | US$40.00 | PB11.6x | E59.0% | n/a | ||
| BPMCBlueprint Medicines | US$87.93 | 18.9% | 94.4% | US$5.3b | US$81.61 | PS24.7x | E52.6% | n/a | ||
| HALOHalozyme Therapeutics | US$39.02 | -2.3% | -31.4% | US$5.2b | US$51.27 | PE20.3x | E23.5% | n/a | ||
| NUVLNuvalent | US$80.28 | 13.6% | 171.5% | US$5.0b | US$75.43 | PB12.7x | E-13.3% | n/a | ||
| CRSPCRISPR Therapeutics | US$62.08 | -3.8% | 33.8% | US$4.9b | US$85.70 | PS29x | E46.5% | n/a | ||
| ACADACADIA Pharmaceuticals | US$28.58 | 36.2% | 85.7% | US$4.7b | US$32.72 | PS7.4x | E60.3% | n/a | ||
| MDGLMadrigal Pharmaceuticals | US$237.13 | 13.8% | 271.7% | US$4.7b | US$315.92 | PB210.4x | E73.4% | n/a |